Valentyn S. Svintsitskiy

33/43 Lomonosova Str
03022, Ukraine

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Corrigendum to "SUROVA Study: Global Real-World Treatment Strategies And Mortality Risk Prediction In Advanced Ovarian Cancer" [International Journal of Gynecological Cancer 36 (2026) 102688].

Corrigendum to "SUROVA Study: Global Real-World Treatment Strategies And Mortality Risk Prediction In Advanced Ovarian Cancer" [International Journal of Gynecological Cancer 36 (2026) 102688].

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 30, 2026

Early death and early relapse in advanced ovarian cancer: distinct clinical phenotypes in the International SUROVA cohort.

Early death and early relapse in advanced ovarian cancer: distinct clinical phenotypes in the International SUROVA cohort.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 19, 2026

SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer.

SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 12, 2025

Ovarian Epithelioid Hemangioendothelioma. Case Report.

Ovarian Epithelioid Hemangioendothelioma. Case Report.

Journal: Experimental oncology

Published: February 20, 2025

Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial.

Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: February 27, 2024

Features of recurrence of endometrioid type endometrial cancer of I stage.

Features of recurrence of endometrioid type endometrial cancer of I stage.

Journal: Experimental oncology

Published: December 30, 2021

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 01, 2021

Experience with the use of HIPEC in advanced serous ovarian cancer after complete and optimal cytoreduction.

Experience with the use of HIPEC in advanced serous ovarian cancer after complete and optimal cytoreduction.

Journal: Experimental oncology

Published: March 31, 2021

RADIATION AND CHEMORADIATION THERAPY FOR I STAGE INTERMEDIATE AND HIGH/INTERMEDIATE ENDOMETRIAL CANCER - DESCRIPTIVE ANALYSIS.

RADIATION AND CHEMORADIATION THERAPY FOR I STAGE INTERMEDIATE AND HIGH/INTERMEDIATE ENDOMETRIAL CANCER - DESCRIPTIVE ANALYSIS.

Journal: Problemy radiatsiinoi medytsyny ta radiobiolohii

Published: March 23, 2021

Recurrence of borderline ovarian tumors.

Recurrence of borderline ovarian tumors.

Journal: Experimental oncology

Published: July 06, 2013

Showing 1-10 of 10

Last Updated: 09/26/2026